eteplirsen brand name exondys medication treat cure types duchenne muscular dystrophy dmd caused specific mutation eteplirsen targets specific mutations used treat dmd eteplirsen form antisense therapy eteplirsen developed steve wilton sue fletcher colleagues university western australia commercialized sarepta controversial debate surrounding drugs efficacy two fda review panel members resigned protest eteplirsen received accelerated approval us food drug administration late committee medicinal products human use chmp european medicines agency ema refused authorize use following adverse events observed least people received eteplirsen trials vomiting contusion excoriation arthralgia rash catheter site pain upper respiratory tract duchenne muscular dystrophy caused mutation dmd gene changes dmd mrna longer codes functional dystrophin protein usually due nonsense mutation introduces premature stop codon mrnacitation needed exon appropriate number bases lies near mutation removing defective exon downstream reading frame corrected production partially functional dystrophin restoredcitation needed general strategy used designing exonskipping oligos dmd exons transcribed longest splice form dystrophin transcript many different oligos needed address range mutations present population people dmdcitation needed eteplirsen morpholino antisense oligomer triggers excision exon premrna splicing dystrophin rna transcript skipping exon changes downstream reading frame giving eteplirsen healthy person would result production dystrophin mrna would code functional dystrophin protein dmd patients particular nonsense mutations giving eteplirsen restore reading frame dystrophin mrna result production functional although modified internal deletion consisting patients original defect well therapeutically skipped exon eteplirsen given intravenous infusion systemic treatment dmd exon skipping induced eteplirsen chargeneutral phosphorodiamidate morpholino oligomer pmo selectively binds exon dystrophin premrna restoring phase reading frame enabling production functional internally edited uncharged nature pmo helps make resistant biological modified dystrophin protein produced eteplirsen may cause less severe form dystrophinopathy much like becker muscular dystrophy eteplirsens proposed mechanism action bind dystrophin premrna alter exon splicing rna almost fulllength dystrophin made increasing quantity abnormal potentially functional dystrophin protein objective slow prevent progression eteplirsen morpholino phosphorodiamidate antisense oligomer ctccaacatcaaggaagatggcatttctag sequence source us fda eteplirsen briefing document nda g cg predicted tm Î¼m oligo oligo complement ctagaaatgccatcttccttgatgttggag exon ensemblorg rna target site marked given target site within exon likely blocking binding exonic splice enhancer protein altering splicing interfering splice regulation ctcctactcagactgttactctggtgacacaacctgtggttactaaggaaactgccatct ccaaactagaaatgccatcttccttgatgttggaggtacctgctctggcagatttcaacc gggcttggacagaacttaccgactggctttctctgcttgatcaagttataaaatcacaga gggtgatggtgggtgaccttgaggatatcaacgagatgatcatcaagcagaag following single multiple intravenous infusions majority drug elimination occurred within hours intravenous administration elimination halflife eteplirsen new drug applications nda eteplirsen similar drug drisapersen filed us food drug administration fda august prescription drug user fee act pdufa goal dates december drisapersen february eteplirsen following fda rejection drisapersen agency announced threemonth time extension review eteplirsen fda panel decision controversial fda staff panel used stricter standard evidence sarepta patient groups used fda panel said required law apply standard substantial evidence effectiveness required randomized controlled trials showing effectiveness meaningful clinical outcome ability function daily life sarepta patient groups wanted use standard historical controls personal testimonies presence altered dystrophin body april advisory committee panel voted however june fda requested additional data sarepta confirm findings dystrophin production eteplirsen janet woodcock director fdas center drug evaluation research overruled panel fda commissioner robert califf deferred decision eterplirsen received accelerated approval september european medicines agency reviewed molecule refused approve following approval eteplirsen two drugs similar kind golodirsen viltolarsen received provisional approval fda treatment people confirmed mutation dystrophin gene amenable exon well casimersen exon us list price eteplirsen per year treatment institute clinical economic review found drug cost effective list price cost one qualityadjusted life year qaly equal httpsenwikipediaorgwikieteplirsen